Monaco Asset Management Sam Adverum Biotechnologies, Inc. Transaction History

Monaco Asset Management Sam

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 07, 2024	BUY	$0.75 - $1.26 $15,000 - $25,200	20,000 Added 33.76%	79,234 $59,000
Q3 2023 Nov 07, 2023	SELL	$1.5 - $2.33 $263,649 - $409,534	-175,766 Reduced 74.79%	59,234 $88,000
Q2 2023 Aug 08, 2023	SELL	$0.68 - $1.59 $288,711 - $675,074	-424,575 Reduced 64.37%	235,000 $373,000
Q4 2022 Jan 31, 2023	BUY	$0.54 - $10.3 $234,670 - $4.48 Million	434,575 Added 193.14%	659,575 $382,000
Q3 2022 Oct 31, 2022	SELL	$0.96 - $9.68 $213,123 - $2.15 Million	-222,004 Reduced 49.66%	225,000 $214,000
Q2 2022 Aug 01, 2022	BUY	$0.81 - $1.34 $362,073 - $598,985	447,004 New	447,004 $536,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Monaco Asset Management Sam, based on Form 13F filings with the SEC.

Stay updated on Monaco Asset Management Sam with notifications on news.